Laman UtamaMLLCF • OTCMKTS
add
Molecular Partners AG
Tutup sebelumnya
$6.52
Julat tahun
$3.40 - $10.14
Permodalan pasaran
245.02J USD
Bilangan Purata
53.00
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
SWX
Berita pasaran
NVDA
2.48%
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
(CHF) | Mac 2024info | Perubahan T/T |
---|---|---|
Hasil | 2.74J | -10.23% |
Perbelanjaan pengendalian | 4.49J | -17.47% |
Pendapatan bersih | -11.32J | 23.37% |
Margin untung bersih | -413.62 | 14.63% |
Pendapatan bagi setiap syer | — | — |
EBITDA | -15.25J | -5.35% |
Kadar cukai berkesan | — | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
(CHF) | Mac 2024info | Perubahan T/T |
---|---|---|
Pelaburan tunai dan jangka pendek | 174.13J | -25.06% |
Jumlah aset | 185.60J | -24.10% |
Jumlah liabiliti | 17.06J | -23.74% |
Jumlah ekuiti | 168.54J | — |
Syer tertunggak | 32.87J | — |
Harga kepada buku | 1.27 | — |
Pulangan pada aset | -20.65% | — |
Pulangan pada modal | -22.53% | — |
Aliran Tunai
Perubahan bersih dalam tunai
(CHF) | Mac 2024info | Perubahan T/T |
---|---|---|
Pendapatan bersih | -11.32J | 23.37% |
Tunai daripada operasi | -17.05J | -3.05% |
Tunai daripada pelaburan | 17.61J | 422.58% |
Tunai daripada pembiayaan | -300.00K | -1.01% |
Perubahan bersih dalam tunai | 1.04J | 107.39% |
Aliran tunai bebas | -11.21J | -30.15% |
Perihal
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Diasaskan
2004
Tapak web
Pekerja
168